Author

Emmanuelle Kaltenbach

Observed name: E Kaltenbach

Institution: Ipsen (United Kingdom)

Observed institution: Ipsen (United Kingdom)

ORCID: 0000-0002-4916-0465

Observed ORCID: 0000-0002-4916-0465

OpenAlex ID: A5064899004

How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?

2021 · Marius Huguet, Véronique Raimond, et al. · Bulletin du Cancer · 15

Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health

2021 · Véronique Raimond, Emmanuelle Kaltenbach, et al. · Bulletin du Cancer · 5

A Noninterventional, Cross-Sectional Study to Assess Patient Prostate Cancer Treatment Preferences and Experiences in Europe

2025 · Emmanuelle Kaltenbach, Ana Maria Rodriguez-Leboeuf, et al. · Advances in Therapy · 1

Supplementary material: Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome

2026 · Emmanuelle Kaltenbach, Alice Guiraud-Diawara, et al. · Figshare

Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome

2026 · Emmanuelle Kaltenbach, Alice Guiraud-Diawara, et al. · Journal of Comparative Effectiveness Research

Sa44 Indirect Treatment Comparison of Odevixibat and Maralixibat for the Treatment of Cholestatic Pruritus in Patients With Alagille Syndrome (algs)

2026 · Emmanuelle Kaltenbach, Alice GUIRAUD-DIAWARA, et al. · Value in Health

Letter to The Editor, Regarding “Indirect Comparison of Maralixibat and Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis” Recently Published by Lacey and Colleagues

2025 · Emmanuelle Kaltenbach, Virginie Jacquemin, et al. · Clinical Therapeutics

EE262 Cost-Consequence Analysis of Cabozantinib in Combination With Nivolumab in Treatment of First-Line Advanced Renal Cell Carcinoma in Germany: A Payer Perspective

2024 · D Gultyaev, E Kaltenbach, et al. · Value in Health

OP310 Challenges Raised By The Economic Evaluation Of CAR-T-cell therapies: The Review By The French National Authority For Health

2021 · Véronique Raimond, Emmanuelle Kaltenbach, et al. · International Journal of Technology Assessment in Health Care

Works count: 9

Citation count: 21

H-index: 2

I10-index: 1